Most Viewed Articles
| Articles | Fulltext downloads | PDF downloads | Total downloads |
|---|---|---|---|
Short CommunicationOutcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in BangladeshFull text |  PDF Year: 2021, Volume: 6, Issue: 1, January-April DOI:10.25259/IJMIO_30_2020 |
11,798 | 1,311 | 13,109 |
Case ReportHyperthermic intraperitoneal chemotherapy in primary peritoneal cancer: Our experience in a young maleFull text | PDF Year: 2021, Volume: 6, Issue: 3, September-December DOI:10.25259/IJMIO_16_2021 |
11,942 | 89 | 12,031 |
New Drug UpdateAmlodipine-induced inhibition of NFAT-2 nuclear translocation and its utility as an additive to immune checkpoint inhibitorFull text | PDF Year: 2021, Volume: 6, Issue: 3, September-December DOI:10.25259/IJMIO_13_2021 |
11,312 | 113 | 11,425 |
NewsEditorial board tribute to Dr. Amit VermaFull text | PDF Year: 2021, Volume: 6, Issue: 3, September-December |
10,619 | 100 | 10,719 |
ErratumErratum for manuscript “Muir Torre Syndrome – An Indian Case report” (IJMIO_5_2020)Full text | PDF Year: 2021, Volume: 6, Issue: 2, October DOI:10.25259/IJMIO_05_2020_ER |
10,146 | 68 | 10,214 |
EditorialNanobytesFull text | PDF Year: 2019, Volume: 4, Issue: 3, September-December DOI:10.25259/IJMIO_7_2019 |
5,158 | 4,694 | 9,852 |
Conference Review6th Molecular Oncology Society Conference: Improving patient survival by molecularly targeted therapiesFull text | PDF Year: 2021, Volume: 6, Issue: 3, September-December DOI:10.25259/IJMIO_20_2021 |
9,486 | 154 | 9,640 |
Short CommunicationDriver mutations in oncogenesisFull text | PDF Year: 2021, Volume: 6, Issue: 2, May-August DOI:10.25259/IJMIO_26_2020 |
8,607 | 649 | 9,256 |
Review ArticleThe evolving role of precision medicine in the management of advanced sarcomas – A mini reviewFull text | PDF Year: 2021, Volume: 6, Issue: 3, September-December DOI:10.25259/IJMIO_6_2021 |
9,048 | 146 | 9,194 |
Review ArticleImmune dynamics of SARS-CoV-2 virus evolutionFull text | PDF Year: 2022, Volume: 7, Issue: 1, January-April DOI:10.25259/IJMIO_26_2021 |
7,357 | 1,680 | 9,037 |
Review ArticleImmuno-oncology of differentiated thyroid cancerFull text | PDF Year: 2021, Volume: 6, Issue: 2, May-August DOI:10.25259/IJMIO_36_2020 |
7,591 | 1,112 | 8,703 |
Review ArticleA compendium of population wide DNA methylation profile for oral cancer in IndiaFull text | PDF Year: 2021, Volume: 6, Issue: 2, May-August DOI:10.25259/IJMIO_2_2021 |
7,308 | 1,352 | 8,660 |
Case SeriesDual driver in non-small cell lung carcinoma – therapeutic dilemmaFull text | PDF Year: 2022, Volume: 7, Issue: 1, January-April DOI:10.25259/IJMIO_22_2021 |
8,498 | 159 | 8,657 |
Brief CommentaryERBB and FGFR2 pathway inhibition in biliary tract cancers – Dawn of a new beginningFull text | PDF Year: 2021, Volume: 6, Issue: 3, September-December DOI:10.25259/IJMIO_10_2021 |
8,446 | 68 | 8,514 |
Review ArticlePost-chemotherapy maintenance treatment by nicotinamide riboside, a poly ADP ribose polymerase 1 inhibitor, in BRCA mutated advanced ovarian cancer – A perspectiveFull text | PDF Year: 2021, Volume: 6, Issue: 3, September-December DOI:10.25259/IJMIO_12_2021 |
8,171 | 108 | 8,279 |
Case ReportUnusual presentation of an Epstein barr virus-negative extranodal natural killer/T cell lymphoma: A diagnostic dilemmaFull text | PDF Year: 2022, Volume: 7, Issue: 1, January-April DOI:10.25259/IJMIO_18_2021 |
8,067 | 83 | 8,150 |
Brief CommentaryBioactive lipid: A novel diagnostic approach for retinoblastoma in clinical managementFull text | PDF Year: 2021, Volume: 6, Issue: 3, September-December DOI:10.25259/IJMIO_7_2021 |
7,686 | 288 | 7,974 |
Original ArticleReal World Outcomes of Check Point Inhibitors Immunotherapy in Renal and Urothelial Cancers in a Teratiary Care Cancer Center in IndiaFull text | PDF Year: 2019, Volume: 4, Issue: 3, September-December DOI:10.25259/IJMIO_1_2019 |
3,614 | 3,951 | 7,565 |
EditorialMisleading and Biased Lancet Editorial on Kashmir: What are the Authors Hiding?Full text | PDF Year: 2019, Volume: 4, Issue: 3, September-December DOI:10.25259/IJMIO_8_2019 |
3,361 | 3,937 | 7,298 |
Position PaperPractical consensus recommendations – Current role of immune response evaluation criteria in solid tumors criteria in the management of cancer patients receiving immunotherapyFull text | PDF Year: 2019, Volume: 4, Issue: 1, January-April DOI:10.25259/IJMIO-6-2019 |
4,158 | 2,925 | 7,083 |
Case ReportMetastatic endometrial carcinoma responsive to pembrolizumabFull text | PDF Year: 2021, Volume: 6, Issue: 1, January-April DOI:10.25259/IJMIO_18_2020 |
4,670 | 2,325 | 6,995 |
Case ReportComplete metabolic response with letrozole and palbociclib in advanced breast cancerFull text | PDF Year: 2019, Volume: 4, Issue: 3, September-December DOI:10.25259/IJMIO_2_2019 |
4,164 | 2,668 | 6,832 |
Review ArticleCell biological basis of tumor relapse and recurrence – A help from yeast quiescent biology and neuronal quiescent cell biologyFull text | PDF Year: 2020, Volume: 5, Issue: 1, January-April DOI:10.25259/IJMIO_18_2019 |
3,951 | 2,863 | 6,814 |
Original ArticleAdvanced lung cancer and molecular testing in the middle of coronavirus disease 2019 second wave in the South Asian association for regional cooperation regionFull text | PDF Year: 2021, Volume: 6, Issue: 2, May-August DOI:10.25259/IJMIO_15_2021 |
5,940 | 747 | 6,687 |
Review ArticleIs continuous infusion of high-dose ifosfamide, a safe option? Drug reviewFull text | PDF Year: 2020, Volume: 5, Issue: 2, May-August DOI:10.25259/IJMIO_21_2019 |
5,220 | 1,436 | 6,656 |
